In our study, it is worth noting that although PD-1 did not perform as well as LAG-3 in predicting LAM, it showed significant downregulation in LAM patients and played an important role in identifying the subgroup without increased serum VEGF-D and the subgroup with comorbidities. The gene discussed is VEGFD; the disease is lymphangioleiomyomatosis.